Diagnosing diseases is basically the frontlines when it comes to fighting against illnesses and how effectively and efficiently this is done will affect how the rest of the battle goes. Unfortunately, diagnosis can be expensive, depending on the disease. Thanks to a new microchip, which can cost only $0.1 to create, this might not be a problem anymore.
The microchip in question was created by a team of engineers from Stanford who published their findings in the Proceedings of the National Academy of Sciences. Not only is the chip tiny, it’s also incredibly inexpensive to produce and can be manufactured at a large scale in a very short period of time.
“For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability,” the paper reads. “To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform.”
Calling it the FNIP chip, the researchers created the device with three layers of varying expendability. As for how it is used, it’s basically a two-step process. First, the user would need to customize the configuration in order to suit the particular disease that needs to be diagnosed, Futurism reports. Next, the necessary samples for analysis can then be printed onto the top layer of the chip.
So, which diseases can this microchip detect? So far, the researchers tested it to analyze cancer fluid and succeeded. They also used it to diagnose immune cells and was able to pull off similar results as another diagnostic tool that would have cost $100,000 in comparison.
Before anyone gets too excited, however, the researchers are saying that it would take some time before the microchip becomes widely available. There are some hurdles to overcome first, including more tests to see if the platform is even safe to use.


Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
3 clinical-grade skincare creams you really shouldn’t buy online
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 



